Adherence and persistence with istradefylline treatment in patients with Parkinson's disease in the United States. [PDF]
Joseph R+5 more
europepmc +1 more source
The Changing Face of Dystonia—Enhancing Diagnosis by Moving Beyond Traditional Clinical Phenotyping
Movement Disorders Clinical Practice, EarlyView.
Niroshan Jeyakumar, Kishore R. Kumar
wiley +1 more source
Neuronal α‐Synuclein Disease Stage Progression over 5 Years
Abstract Background Neuronal α‐synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha‐synuclein (n‐asyn) pathology. The NSD integrated staging system (NSD‐ISS) for research describes progression across the disease continuum as stages 0 to 6.
Tanya Simuni+205 more
wiley +1 more source
Levodopa modulates small‐world architecture of functional brain networks in Parkinson's disease
B. Berman+6 more
semanticscholar +1 more source
Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. [PDF]
Kassubek J+8 more
europepmc +1 more source
Bridging Clinical Expertise and Digital Innovation: Toward a Modern Phenomenology of Parkinsonism
Movement Disorders Clinical Practice, EarlyView.
Genko Oyama
wiley +1 more source
Abstract Background Glial cell line–derived neurotrophic factor (GDNF) is required for development and survival of dopaminergic neurons. A previous trial evaluating lower‐dose adeno‐associated virus serotype 2–GDNF (AAV2‐GDNF) bilateral intraputaminal infusion in participants with advanced Parkinson's disease (PD) achieved 26% mean putaminal coverage ...
Amber D. Van Laar+10 more
wiley +1 more source
Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson's disease. [PDF]
Miyaue N+8 more
europepmc +1 more source
Early Levodopa Therapy in Tyrosine Hydroxylase Deficiency
Movement Disorders Clinical Practice, EarlyView.
Claudio M. de Gusmao+4 more
wiley +1 more source
Cholinergic System Changes in Dopa‐Unresponsive Freezing of Gait in Parkinson's Disease
Abstract Background Freezing of gait (FoG) is a debilitating mobility disturbance that becomes increasingly resistant to dopaminergic pharmacotherapies with advancing Parkinson's disease (PD). The pathophysiology underlying the response of FoG to dopaminergic treatment is poorly understood.
Kelvin L. Chou+6 more
wiley +1 more source